Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a common diabetes drug prevent heart failure in AF patients?

NCT ID NCT07482020

First seen Apr 11, 2026 · Last updated May 24, 2026 · Updated 5 times

Summary

This study tests whether SGLT2 inhibitors, a type of diabetes drug, can improve the heart's upper chamber function in people with intermittent atrial fibrillation, high blood pressure, and abnormal blood sugar. The goal is to prevent heart failure. About 66 adults will receive either the drug or a placebo, and their heart function will be measured using advanced ultrasound.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fudan University Affiliated Huashan Hospital, Cardiology Department

    RECRUITING

    Shanghai, Shanghai Municipality, 200036, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.